Scotiabank raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $75 from $53 and keeps an Outperform rating on the shares. The firm increased its price target on the stock given the promising results presented for its phase 3 ENERGIZE-T study as well as its announcement it filed for the regulatory approval of mitapivat for the treatment of thalassemia in four regions, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios presents results from Phase 3 ENERGIZE-T Study of Mitapivat
- Agios Pharmaceuticals to present new data on mitapivat, tebapivat
- Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank
- Agios Pharmaceuticals Reports Robust Q3 2024 Results
- Agios Pharmaceuticals reports Q3 EPS $16.22, consensus $1.11